Pharmaron Beijing Co., Ltd.* 3759 2022 6 30 6 30 2022 2021 % 4,634,585 3,285,511 41.1 1,613,111 1,189,711 35.6 585,432 564,837 3.6 812,106 651,392 24.7 858,787 845,064 1.6 4,634.6 2021 6 30 1,349.1 41.1% 585.4 2021 6 30 3.6% 858.8 2021 6 30 1.6% 2022 6 30 2022 6 30 2021 1 2022 6 30 6 30 2022 2021 4 4,634,585 3,285,511 (3,021,474) (2,095,800) 1,613,111 1,189,711 5 220,661 119,881 5 (146,209) (109,595) (108,110) (63,733) (661,073) (383,583) (83,669) (64,464) ╱ 撥回 (6,339) 472 (81,235) (15,786) (4,439) (6,993) 6 742,698 665,910 7 (177,398) (118,610) 565,300 547,300 585,432 564,837 (20,132) (17,537) 565,300 547,300 9 0.4941 0.4751 9 0.4939 0.4747 2 2022 6 30 6 30 2022 2021 565,300 547,300 ╱ (27,846) (28,626) (10,307) 10,947 (38,153) (17,679) (38,153) (17,679) 527,147 529,621 548,419 547,136 (21,272) (17,515) 527,147 529,621 3 2022 6 30 2022 2021 6 30 12 31 6,516,770 5,577,904 1,177,845 726,800 2,535,957 2,096,265 229,329 227,163 597,363 452,606 248,311 310,063 193,584 143,233 34,418 15,595 431,624 195,993 11,965,201 9,745,622 285,032 181,700 197,271 165,625 10 1,616,062 1,228,849 276,401 194,981 441,403 332,715 739,186 1,441,191 587,004 1,537,947 10,631 16,674 111,940 17,243 2,736,741 3,526,577 7,001,671 8,643,502 489,669 482,302 11 466,382 315,534 1,352,082 1,327,910 9,449 – 836,714 679,621 134,552 95,292 106,483 81,337 3,395,331 2,981,996 3,606,340 5,661,506 15,571,541 15,407,128 4 2022 2021 6 30 12 31 583,955 956,095 205,245 173,300 92,614 81,559 158,507 149,439 3,614,049 3,467,090 628,051 284,338 5,282,421 5,111,821 10,289,120 10,295,307 12 1,191,068 794,177 (484,161) (301,825) 198,554 198,554 9,250,119 9,438,335 10,155,580 10,129,241 133,540 166,066 10,289,120 10,295,307 5 2022 6 30 1. 2004 7 1 2019 1 28 300759.SZ 2019 11 28 3759.HK 6 1 8 CMC CDMO 2.1 2022 6 30 34 2021 12 31 2.2 2021 12 31 3 16 2021 6 30 16 37 1 2018 2020 9 16 41 6 a) 3 2018 6 3 37 21 3 37 21 2022 1 1 b) 16 2021 1 1 2021 1 1 c) 37 37 2022 1 1 d) 2018 2020 1 9 16 41 9 2022 1 1 16 16 13 16 16 9 7 3. (CADD) CMC CDMO (CDMO) (CDMO) CMC 2022 6 30 CDMO 2,860,148 1,084,625 584,537 95,470 9,805 4,634,585 1,242,702 356,932 29,883 (18,938) 2,532 1,613,111 220,661 (146,209) (108,110) (661,073) (83,669) (6,339) (81,235) (4,439) 742,698 8 CMC 2021 6 30 CDMO 2,027,048 762,243 422,691 71,661 1,868 3,285,511 848,521 278,517 59,614 2,159 900 1,189,711 119,881 (109,595) (63,733) (383,583) (64,464) 472 (15,786) (6,993) 665,910 (a) 6 30 2022 2021 3,042,305 2,136,045 629,646 564,435 112,287 77,995 819,977 492,991 30,370 14,045 4,634,585 3,285,511 9 (b) 2022 2021 6 30 12 31 8,353,308 6,680,284 1,408,274 1,318,092 1,892,290 1,386,584 28,600 35,004 11,682,472 9,419,964 4. 6 30 2022 2021 4,634,585 3,283,643 – 1,868 4,634,585 3,285,511 (a) 6 30 2022 2021 2,860,148 2,027,048 CMC CDMO 1,084,625 762,243 584,537 422,691 95,470 71,661 9,805 – 4,634,585 3,283,643 2,454,749 1,776,503 2,179,836 1,507,140 4,634,585 3,283,643 10 (b) FTE FFS FTE 15 FTE FFS 5. 6 30 2022 2021 23,302 19,884 5,932 5,930 9,627 17,584 38,861 43,398 – 17,057 180,190 – – 27,705 – 5,918 – 25,452 492 – 1,118 351 181,800 76,483 220,661 119,881 (36,844) (2,961) (167) (872) (8,179) – (1,446) – (80,728) – (11,055) (100,395) (7,790) (5,367) (146,209) (109,595) 11 6. 6 30 2022 2021 265,257 207,380 60,085 49,459 344 15,081 12,108 * 1,667,264 1,106,238 ** 442,111 310,516 52,062 25,720 (25,452) (180,190) – (492) – 8,179 (27,705) 80,728 (17,057) 2,543 1,252 6,339 (472) 1,446 (5,918) 11,055 100,395 2,380 2,150 * ** 12 7. 6 30 2022 2021 164,173 119,638 13,225 (1,028) 177,398 118,610 8. 2022 5 31 2021 A H 2021 12 31 0.45 357,320,000 2022 6 30 301,118,000 2021 6 30 9. 6 30 2022 2021 585,432 564,837 (501) (694) 584,931 564,143 501 347 585,432 564,490 13 6 30 2022 2021 1,183,746,632 1,187,504,118 1,601,168 1,558,409 1,185,347,800 1,189,062,527 2022 3 28 2022 5 31 10 5 397,023,000 10. 2022 2021 6 30 12 31 1 1,603,490 1,209,375 1 2 12,572 19,474 1,616,062 1,228,849 8,494,000 2021 12 31 7,366,000 14 11. 2022 2021 6 30 12 31 1 459,574 309,449 1 6,808 6,085 466,382 315,534 2022 6 30 2021 12 31 4,000 30 12. 2022 2021 6 30 12 31 1,191,068 794,177 2021 12 31 2022 1 1 794,177,098 794,177 A (132,012) (132) 397,022,543 397,023 2022 6 30 1,191,067,629 1,191,068 15 A. 1. CMC CDMO B. 1. 2022 4,634.6 41.1% 1,613.1 34.8% 585.4 3.6% 812.1 24.7% 177.4 49.6% 2022 6 30 17,650 15,820 89.6% 2021 12 31 2,365 16 90% 20 20 14.4% 2022 400 65.6% 13.6% 17.7% 3.1% 1,314.2 27.0% CMC CDMO 853.6 11 1,300 2022 12.1% 5 Science Based Targets initiative SBTi 2022 6 22 (SBTi Commitment Letter) SBTi 2. (1) 2,860.1 41.1% 43.4% 1.5 73.9% 11.3% 11.7% 3.1% 17 2022 6 30 8,492 2021 12 31 1,356 5,800 47.5% 1.8 576 (IND) (NDA) 52 48 (IND) 120,000 2021 42,000 2,000 105,000 2024 140,000 2024 100% 18 (2) CMC CDMO CMC CDMO 1,084.6 42.3% 32.9% 3.6 CMC CDMO 64.8% 20.1% 13.1% 2.0% CMC CDMO CMC CDMO 2022 6 30 CMC CDMO 3,601 2021 12 31 980 CMC CDMO 76% 714 500 I-II 182 III 22 10 81,000 2021 600 200 2022 400 2022 2022 1 7 Cramlington Aesica Pharmaceuticals Limited Pharmaron Manufacturing Services (UK) Ltd Coventry cGMP (FDA) API Cramlington Coventry CMC CDMO III CMC CDMO 19 (3) 584.5 38.3% 5.1% 9.0% 24.8% 12.6% 57.2% 5.4% 2022 6 30 3,329 CRC SSU 68.4% 2022 6 30 970 800 1,997 140 600 1,100 20 (4) 95.5 33.2% -19.8% 84.2% 14.5% 1.3% CDMO 2022 6 30 398 2021 12 31 57 CDMO 70,000 2023 GMP 200L 2,000L 21 CDMO IND GLP ELISpot) GMP GMP GMP 2020 95% GMP non-GLP GLP GLP CGT GMP 50 CGT 19 2 40 non-GLP GLP 22 2021 Pharmaron Biologics UK CDMO QC/QA CDMO 500L SUB GMP 50L 500L SUBs GMP 100 QC/QA (CQA) QC/QA FDA EMA MHRA CDMO 2021 20 CDMO 3. 585.4 2021 6 30 564.8 3.6% 4. 0.4941 2021 6 30 0.4751 4.0% 0.4939 2021 6 30 0.4747 4.0% 23 5. (i) (ii) (iii) 2022 2021 6 30 6 30 585,432 564,837 42,609 21,932 65,555 106,804 32,356 (9,937) 725,952 683,636 86,154 (32,244) 812,106 651,392 24 6. 858.8 2021 6 30 13.7 1.6% 57.0 2021 6 30 2,167.9 97.4% -1,067.3 2021 6 30 5,005.3 127.1% 7. 2022 6 30 2,736.7 858.8 2022 6 30 7,001.7 2021 12 31 8,643.5 3,395.3 2021 12 31 2,982.0 2022 6 30 2.1 2021 12 31 2.9 25 8. 2022 6 30 1,073.6 489.6 584.0 2022 6 30 45.8% 2021 12 31 44.0% 9. 2022 6 30 412.6 2021 12 31 422.5 120.3 2021 12 31 135.3 2022 6 30 111.9 2021 12 31 17.2 10. 2022 6 30 11. 2022 6 30 12. (1) Aesica Pharmaceuticals Limited 100% 2021 12 Pharmaron UK Limited 5,500 47,335.2 Cramlington Aesica Pharmaceuticals Limited Pharmaron Manufacturing Services (UK) Ltd 100% 2022 1 100 cGMP (FDA) (MHRA) CDMO 26 (2) 2022 2 (3) 2021 5 27 27 (4) 100% 2022 3 28 100% 2022 4 85,242,000 2022 3 27 2022 4 19 2022 5 6 (5) 2021 2022 5 31 2021 2021 (i) 0.45 (ii) 2022 6 13 (10) (5) 794,045,086 660,028,586 A 134,016,500 H 397,022,543 330,014,293 A 67,008,250 H 2022 5 6 2022 5 31 (6) H 2022 5 31 2021 H 250.75 H 166.42 H 229.50 H 152.32 2022 6 14 H 2021 2022 6 13 28 (7) 2019 A 2022 1 14 17.85 2019 A 132,012 A 2 2022 5 2022 5 13 2019 A 1,112,834 A (8) 2022 A 2022 5 31 2022 A 2022 A 2022 A 2022 A A 1,548,800 A 0.20% A 25% 25% 25% 25% 2022 A 2022 5 6 29 (9) H 76 2020 H H 25% H 183,075 76 4 21,188 H H 5 H 42,300 H 2022 6 10 H 2020 2022 6 2 2021 10 5 2020 2022 4 1 H H 44 751,110 H 2022 5 31 H H 131 7,588,450 H 2021 H 25% 25% 25% 25% 30 C. 1 31 (1) CADD GMP GMP (2) 2018 AMS ADME Absorption Systems DMPK/ADME DMPK (3) POC 32 IND (4) IND CRO 33 (5) IND IND 2020 ICH GLP/GCP/GMP 2021 Pharmaron Biologics UK GMP NMPA FDA OECD GLP IND 2 20 11 IND IND 34 Cramlington Hoddesdon 3 (DEL) 3D 35 4 Boliang LOU 30 10 2 15 2,800 2022 6 30 15,820 36 5 2022 400 90% 37 2022 A. 1. (1) 2021 5,661 2026 7,771 2021 2026 6.5% 2021 5,620 2026 9,566 2021 2026 11.2% (2) 2021 1,403 2026 2,477 2021 2026 12% 2021 11.9% 2026 3,424 21.4% 38 a. 2021 CRO 159 CRO 46.0% 2026 320 2021 2026 15.0% 64.2% 2021 CRO 168 16.3% 2026 512 24.6% b. (CDMO) 2021 CDMO 637 2026 CDMO 1,188 2021 2026 13.3% 2021 CDMO 432 CMO 10.5% 2026 CDMO 1,526 19.8% c. 2021 500 CRO 42.9% 2026 797 2021 2026 9.8% 47.8% 2021 316 9.8% 2026 1,003 19.4% 39 2. 40 3. 2022 2022 (1) 2022 2022 CDMO (2) 2022 CDMO 2022 CDMO 41 3 (4) 2022 2022 (5) 2022 2022 (6) 42 (7) 2022 1 Hoddesdon Liverpool Rushden 2 CGT San Diego Exton 3 CDMO 4. (1) 43 (2) (3) 44 (4) FDA NMPA (5) 2015 45 (6) (7) (8) CMC CDMO 46 (9) (10) 47 A. H 4,522.7 2022 6 30 213.7 2019 11 14 2022 6 30 2022 2022 6 30 6 30 (1) 2022 6 30 30.0% 1,356.8 1,356.8 – 2022 6 30 19.5% 881.9 881.9 – 2022 6 30 4.5% 203.5 203.5 – 2022 6 30 6.0% 271.4 271.4 – 2022 6 30 10.0% 452.3 452.3 – 48 2022 2022 6 30 6 30 (1) 2022 6 30 20.0% 904.5 904.5 – 2022 12 31 15.0% 678.4 464.7 213.7 CRO CMO 2022 6 30 15.0% 678.4 678.4 – 2022 6 30 10.0% 452.3 452.3 – 100% 4,522.7 4,309.0 213.7 49 B. 2021 6 18 300 1,916 2021 6 8 2021 6 9 2021 6 11 2021 6 18 2021 6 21 3,776.0 2022 6 30 1,829.2 2021 6 21 2022 6 30 2022 2022 6 30 6 30 2024 CMC 12 31 33.3% 1,258.7 628.7 630.0 2024 12 31 33.3% 1,258.7 400.1 858.6 2024 12 31 13.3% 503.4 242.2 261.2 2023 12 31 10.0% 377.6 298.2 79.4 2022 6 30 10.0% 377.6 377.6 – 100% 3,776.0 1,946.8 1,829.2 50 C. 2022 6 30 17,650 2021 12 31 14,923 D. 2022 1 14 17.85 2019 A 132,012 A 2 2022 5 E. Coventry Pharmaron Manufacturing Services (US) LLC 31.5 210.6 Coventry 2022 7 1 cGMP (FDA) (EMA) Cramlington Coventry 2021 A A 2022 7 28 (i) 2021 A A 70.17 46.48 2021 A A 774,200 1,161,300 (ii) 2021 A 185 257,925 A 19 129,600 A 2022 A A 2022 7 28 2022 A 379 2,203,200 A A 38.62 2022 A A 25% 25% 25% 25% 51 F. G. C.2.1 H. 3.21 I. (www.hkexnews.hk) (www.pharmaron.com) 2022 52 2019 A 2019 A 2021 A 2021 A 2021 2021 2021 12 31 2022 A 2022 A AMS A 1.00 H 53 10 5 A H CMC CMO 2004 7 1 A 300759 H 3759 2021 6 18 (i) 300.0 2026 40725 (ii) 1,916.0 2026 40733 CRO 2022 6 13 A H 1 0.45 2021 A H DMPK/ADME 54 A B H H H 2015 9 21 55.89% FDA H H 1961 21 31 1,700 GLP GMP H 1.00 H H IND 55 H A A H H NMPA OECD Pharmaron Biologics Pharmaron Biologics (UK), Ltd. Allergan UK Biologics Limited ( ) , 2021 5 27 55.89% 56 2022 6 30 A 2019 A 2021 A 2022 A A H 2021 6 18 300.0 2026 40725 2021 6 18 1,916.0 2026 40733 A H H SSU 57 % 2022 8 29 * 58